Genprex GNPX

NASDAQ GNPX

$3.43 -0.11 (-3.11%)

At close: Sep 9, 2026 · 4:00 PM EDT

Key Stats

Market Cap1.61 Mn

Div. Yield0.00

Total Debt (Qtr)22,500.00

Add ratio to table…

About

Genprex, Inc. is a clinical stage gene therapy company that develops genetic based treatments for large patient populations with unmet medical needs. The company concentrates on two main areas oncology and diabetes. In oncology it uses a nonviral lipid nanoparticle system called ONCOPREX to deliver tumor suppressor genes such as TUSC2 to cancer cells. In diabetes it employs an adeno associated virus vector carrying the Pdx1 and MafA genes to reprogram pancreatic cells to produce insulin. The company’s therapies are currently in preclinical and clinical stages with no commercial product sales to date. Genprex seeks to address significant gaps in lung cancer care and diabetes management by introducing novel gene based approaches that could complement or improve existing standard of care options.

The company does not generate revenue from product sales at this time. Its current income comes from research collaborations, licensing agreements, and occasional equity financings that support its development programs. All funds are used to advance clinical trials, conduct preclinical studies, and cover general and administrative expenses. Additionally, Genprex occasionally receives grant funding and enters into sponsored research agreements with academic institutions to further validate its technology platforms.

The company operates through the following segments Oncology and Diabetes.

Oncology: This segment focuses on the development of REQORSA a gene therapy that uses the nonviral ONCOPREX delivery system to transport plasmid DNA expressing the TUSC2 tumor suppressor gene into cancer cells. The approach is being tested in combination with approved drugs such as Tagrisso for EGFR mutant non small cell lung cancer, Keytruda for PD1 positive non small cell lung cancer, and Tecentriq for extensive stage small cell lung cancer. The goal is to improve upon existing therapies by reducing tumor glucose metabolism, disrupting cancer cell signaling, restoring apoptosis pathways, and enhancing immune responses. Preclinical studies have shown that REQORSA can synergize with targeted agents and immunotherapies, leading to reduced tumor growth in animal models. The segment also includes efforts to identify additional tumor suppressor genes that could be packaged into the ONCOPREX system for broader oncology applications.
Diabetes: This segment centers on a gene therapy that uses an adeno associated virus vector containing the Pdx1 and MafA transcription factors to reprogram pancreatic alpha cells into insulin producing beta like cells for type 1 diabetes and to rejuvenate exhausted beta cells for type 2 diabetes. The technology is administered via a straightforward endoscopic procedure into the pancreatic duct and is being refined through preclinical work at the University of Pittsburgh. Early animal studies have demonstrated increased C‑peptide levels, improved glucose tolerance, and reduced insulin dependence in diabetic models. The segment also explores the use of alternative promoters such as MafB to fine tune gene expression and enhance the durability of the therapeutic effect.

Genprex occupies a niche within the broader biotechnology sector as a developer of gene based therapies that rely on nonviral delivery for oncology and a pancreatic directed approach for diabetes. It faces competition from larger gene editing companies such as CRISPR Therapeutics and Editas Medicine as well as from established pharmaceutical firms active in lung cancer and diabetes treatment. The company’s competitive advantages stem from its exclusive licenses with MD Anderson for the TUSC2 gene, with the University of Pittsburgh for the diabetes gene construct, from its proprietary ONCOPREX nanoparticle system, and from its focus on combination regimens that may improve efficacy over monotherapies. Additionally, its academic collaborations provide early access to cutting edge research and potential biomarker discovery that could streamline clinical development.

The company’s primary customers are hospitals, clinical trial sites, and patients who enroll in its studies. It also works with academic partners including MD Anderson and the University of Pittsburgh. No specific commercial customers are named because the therapies remain investigational. Patient populations targeted by the oncology segment include individuals with advanced non small cell lung cancer who have progressed on standard EGFR tyrosine kinase inhibitors or immune checkpoint inhibitors, as well as those with extensive stage small cell lung cancer who have received prior chemoimmunotherapy. The diabetes segment aims to serve people with type 1 diabetes who require exogenous insulin and those with type 2 diabetes who have progressive beta cell exhaustion despite conventional therapy.

Investment Thesis

▲ Bull case

Genprex's recent ASCO 2026 abstract revealed that Trop-2 H-scores above 100 and PTEN H-scores below 100 correlated with longer progression-free survival in NSCLC patients treated with Reqorsa, providing a validated biomarker strategy that could significantly improve clinical trial outcomes by enabling precise patient selection for populations most likely to benefit, thereby increasing the probability of positive readouts in ongoing Acclaim-1 and Acclaim-3 trials and strengthening the case for regulatory approval; this predictive capability addresses a critical unmet need in lung cancer therapy where current treatments often lack reliable response markers, positioning Genprex to de-risk clinical development and attract partnership interest from larger oncology players seeking companion diagnostic synergies.
The preclinical data presented at AACR 2026 demonstrated that Reqorsa combined with alectinib achieved 79% tumor shrinkage in ALK+ NSCLC models versus 60% with alectinib alone—a 23% absolute improvement—and in resistant models, the combination produced synergistic tumor reduction with a p-value of 0.0001 versus control, indicating Reqorsa's potential to overcome acquired resistance to tyrosine kinase inhibitors, a major clinical limitation in NSCLC treatment; this dual-mechanism action—direct tumor suppression via TUSC2 restoration and immune modulation via NK cell activation—supports Reqorsa's development as a best-in-class adjunct therapy that could capture significant market share in the ALK+ NSCLC segment, particularly as resistance to first- and second-generation TKIs remains a pervasive challenge with few effective follow-up options.
Genprex's diabetes gene therapy candidate GPX-002 reversed hyperglycemia in Type 2 diabetic mouse models within four weeks via pancreatic delivery of Pdx1/MafA, with evidence of beta-cell maturation and increased mature insulin granules, demonstrating a disease-modifying approach that goes beyond symptomatic treatment to address the root cause of beta-cell exhaustion; this progress, coupled with successful technology transfer to a CDMO and planned FDA IND-enabling meetings, accelerates the path toward human trials for a large underserved population—T2D affects over 37 million Americans—and success here could diversify revenue streams beyond oncology, reduce reliance on single-industry catalysts, and provide non-dilutive funding opportunities through partnerships in the rapidly growing diabetes therapeutics market projected to exceed $100 billion by 2030.

Genprex's recent ASCO 2026 abstract revealed that Trop-2 H-scores above 100 and PTEN H-scores below 100 correlated with longer progression-free survival in NSCLC patients treated with Reqorsa, providing a validated biomarker strategy that could significantly improve clinical trial outcomes by enabling precise patient selection for populations most likely to benefit, thereby increasing the probability of positive readouts in ongoing Acclaim-1 and Acclaim-3 trials and strengthening the case for regulatory approval; this predictive capability addresses a critical unmet need in lung cancer therapy where current treatments often lack reliable response markers, positioning Genprex to de-risk clinical development and attract partnership interest from larger oncology players seeking companion diagnostic synergies.
The preclinical data presented at AACR 2026 demonstrated that Reqorsa combined with alectinib achieved 79% tumor shrinkage in ALK+ NSCLC models versus 60% with alectinib alone—a 23% absolute improvement—and in resistant models, the combination produced synergistic tumor reduction with a p-value of 0.0001 versus control, indicating Reqorsa's potential to overcome acquired resistance to tyrosine kinase inhibitors, a major clinical limitation in NSCLC treatment; this dual-mechanism action—direct tumor suppression via TUSC2 restoration and immune modulation via NK cell activation—supports Reqorsa's development as a best-in-class adjunct therapy that could capture significant market share in the ALK+ NSCLC segment, particularly as resistance to first- and second-generation TKIs remains a pervasive challenge with few effective follow-up options.
Genprex's diabetes gene therapy candidate GPX-002 reversed hyperglycemia in Type 2 diabetic mouse models within four weeks via pancreatic delivery of Pdx1/MafA, with evidence of beta-cell maturation and increased mature insulin granules, demonstrating a disease-modifying approach that goes beyond symptomatic treatment to address the root cause of beta-cell exhaustion; this progress, coupled with successful technology transfer to a CDMO and planned FDA IND-enabling meetings, accelerates the path toward human trials for a large underserved population—T2D affects over 37 million Americans—and success here could diversify revenue streams beyond oncology, reduce reliance on single-industry catalysts, and provide non-dilutive funding opportunities through partnerships in the rapidly growing diabetes therapeutics market projected to exceed $100 billion by 2030.

▼ Bear case

Despite positive biomarker correlations, the ASCO 2026 abstract was based on only 18 patients with available Trop-2 and PTEN H-scores and PFS data, an extremely small sample size that limits statistical robustness and increases the risk of false-positive findings; the follow-up analysis showing 3+ Trop-2 staining had a p-value of 0.053—just outside conventional significance thresholds—further undermines confidence in the biomarker's reliability, and without validation in larger, independent cohorts, there is a substantial risk that these associations will not hold in pivotal trials, potentially leading to failed readouts and wasted investment in patient enrichment strategies that management has not adequately qualified as preliminary or hypothesis-generating.
While Genprex highlights Fast Track and Orphan Drug designations for its lung cancer programs, the Acclaim-1 and Acclaim-3 trials remain Phase 1/2 studies with no disclosed overall survival data, and the company has not provided updated efficacy metrics from ongoing Phase 2 expansions; the Acclaim-1 trial reported only three patients with prolonged PFS in the initial 12-patient dose escalation, and the single partial response case maintained through 60 courses represents an anecdotal outlier rather than reproducible efficacy, raising concerns that the therapy lacks sufficient clinical activity to support registration, especially in competitive NSCLC settings where osimertinib-based regimens already deliver substantial PFS benefits and Reqorsa's incremental value remains unproven in larger, controlled studies.
The diabetes program, though advancing, faces significant translational hurdles: GPX-002's efficacy in NHP models required immunosuppression to mitigate immune responses to AAV vectors, and direct pancreatic injection failed to achieve normal glucose tolerance, suggesting that the proposed endoscopic retrograde cholangiopancreatography delivery method may not be sufficient to overcome immunological barriers in humans; furthermore, the company has not disclosed any toxicology data from NHP studies, and the reliance on preclinical models—where beta-cell rejuvenation was observed—does not guarantee similar outcomes in human T2D, which involves complex pathophysiology including insulin resistance and amyloid deposition, increasing the likelihood of clinical failure despite promising mouse data and exposing the program to high attrition risk typical of early-stage gene therapies.

Despite positive biomarker correlations, the ASCO 2026 abstract was based on only 18 patients with available Trop-2 and PTEN H-scores and PFS data, an extremely small sample size that limits statistical robustness and increases the risk of false-positive findings; the follow-up analysis showing 3+ Trop-2 staining had a p-value of 0.053—just outside conventional significance thresholds—further undermines confidence in the biomarker's reliability, and without validation in larger, independent cohorts, there is a substantial risk that these associations will not hold in pivotal trials, potentially leading to failed readouts and wasted investment in patient enrichment strategies that management has not adequately qualified as preliminary or hypothesis-generating.
While Genprex highlights Fast Track and Orphan Drug designations for its lung cancer programs, the Acclaim-1 and Acclaim-3 trials remain Phase 1/2 studies with no disclosed overall survival data, and the company has not provided updated efficacy metrics from ongoing Phase 2 expansions; the Acclaim-1 trial reported only three patients with prolonged PFS in the initial 12-patient dose escalation, and the single partial response case maintained through 60 courses represents an anecdotal outlier rather than reproducible efficacy, raising concerns that the therapy lacks sufficient clinical activity to support registration, especially in competitive NSCLC settings where osimertinib-based regimens already deliver substantial PFS benefits and Reqorsa's incremental value remains unproven in larger, controlled studies.
The diabetes program, though advancing, faces significant translational hurdles: GPX-002's efficacy in NHP models required immunosuppression to mitigate immune responses to AAV vectors, and direct pancreatic injection failed to achieve normal glucose tolerance, suggesting that the proposed endoscopic retrograde cholangiopancreatography delivery method may not be sufficient to overcome immunological barriers in humans; furthermore, the company has not disclosed any toxicology data from NHP studies, and the reliance on preclinical models—where beta-cell rejuvenation was observed—does not guarantee similar outcomes in human T2D, which involves complex pathophysiology including insulin resistance and amyloid deposition, increasing the likelihood of clinical failure despite promising mouse data and exposing the program to high attrition risk typical of early-stage gene therapies.

Peer group

Peer Comparison

Companies in the Gene and Cell Therapy

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	KRYS	Krystal Biotech, Inc.	primary	10.27 Bn	42.55	23.32	-
2	CRSP	CRISPR Therapeutics AG	primary	5.17 Bn	-10.68	385.71	586.20 Mn
3	IOVA	Iovance Biotherapeutics, Inc.	primary	3.79 Bn	-18.13	11.66	-
4	LEGN	Legend Biotech Corp	primary	3.68 Bn	-174.54	2.89	156.40 Mn
5	QURE	uniQure N.V.	primary	3.05 Bn	-15.49	163.16	50.15 Mn
6	BEAM	Beam Therapeutics Inc.	primary	2.65 Bn	-30.97	16.96	112.43 Mn
7	PGEN	Precigen, Inc.	primary	2.44 Bn	-7.26	28.50	93.88 Mn
8	SRPT	Sarepta Therapeutics, Inc.	primary	2.33 Bn	-16.97	1.18	847.62 Mn

Genprex GNPX

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password